Molecular Characterization and Its Clinical Application of GNAS Variants in Intramuscular Myxoma

Munehisa Kito; Shohei Shigeto; Mai Iwaya; Tomomi Yamaguchi; Masanori Okamoto; Atsushi Tanaka; Akira Takazawa; Hirokazu Ideta; Kaoru Aoki; Hiromasa Hasegawa; Kenji Sano; Tomomi Fujikawa; Tomoki Kosho; Jun Takahashi

doi:10.1002/cam4.71751

March 29, 2026Cancer MedicineOpen Access

Molecular Characterization and Its Clinical Application of GNAS Variants in Intramuscular Myxoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to assess the clinical relevance of GNAS variants in diagnosing intramuscular myxoma (IM).
Used fragment signal analysis to distinguish between intramuscular myxoma and low-grade myxofibrosarcoma (LGMFS).
Evaluated the presence of GNAS R201C/R201H variants in tumor samples.
Fragment signal analysis effectively differentiates IM from LGMFS.
Absence of GNAS R201C/R201H variants does not exclude a diagnosis of IM.

Implication

Fragment signal analysis differentiates intramuscular myxoma from LGMFS, indicating its diagnostic value.

Abstract

These findings suggest that fragment signal analysis is a reasonable diagnostic approach for differentiating IM from LGMFS. However, it is important to recognize that the absence of GNAS R201C/R201H variants does not rule out IM.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kito et al. (2026) studied this question.

synapsesocial.com/papers/69ccb6e416edfba7beb88b16 https://doi.org/10.1002/cam4.71751

View Full Paper

Ask AI

Bookmark

Share

Molecular Characterization and Its Clinical Application of GNAS Variants in Intramuscular Myxoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Molecular Characterization and Its Clinical Application of GNAS Variants in Intramuscular Myxoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading